OncLive Staff

In this episode of How This Is Building Me, Drs Camidge and Garon discuss the importance of continuing to ask a variety of research questions throughout one’s career; the value of negative study results; and the ins and outs of running the lung cancer program and conducting phase 3 clinical trials at UCLA.

The 18th Annual New York Lung Cancers Symposium, scheduled for November 11, 2023, as a live meeting in New York, New York, boasts an agenda that covers a broad range of modern clinical topics.

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.

Over the past 10 years, data from studies including the TAILORx and RxPONDER studies have reshaped treatment standards for patients with hormone receptor–positive, HER2-negative breast cancer.

Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.

The development of novel next-generation hormonal agents is poised to change the landscape for patients with estrogen receptor-positive, HER2-negative breast cancer, offering additional oral solutions to lessen the burden of the invasive delivery of the standard of care and provide agents that are active against acquired variants.

Dr Chuong discusses the evolution of MRI-guided radiation in the cancer treatment armamentarium, the benefits of the MRIdian SMART system, and how Miami Cancer Institute is leading the way with trainings to expand the use of this technology.

Dr Fonkoua discusses the ways in which common clinical trial enrollment criteria in oncology exclude patients from underrepresented groups, enrollment disparities that uniquely affect patients with liver cancer, and initiatives that Mayo Clinic is participating in to eliminate barriers to clinical trial enrollment.

Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.

Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety profile of the STRIDE regimen in this population.

Dr Mirza discusses the FDA approval of dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer; key efficacy and safety findings from the RUBY trial, and ongoing research investigating the role of frontline immune checkpoint inhibitors in patients with endometrial cancer.

In this episode of "How This Is Building Me," Drs Camidge and Vokes discuss the span of countries and institutions along Dr Vokes’ journey to MD Anderson Cancer Center, how Dr Vokes balances research and work in the clinic, and how the correct mentors can help shape career paths in oncology.

Dr Sekeres discusses the FDA approval of quizartinib plus chemotherapy in patients with newly diagnosed, FLT3-ITD–positive AML, key efficacy and safety data from the QuANTUM-First trial, and how this quizartinib regimen addresses an unmet need for older patients in this population.

Dr Trent discusses the need for improved awareness around mutation testing in GIST, the limitations of current clinical trial criteria, and the potential for ctDNA to become a longitudinal cancer monitoring tool, helping to prevent invasive means of measuring disease progression.

Dr Bhatnagar discusses the prior and ongoing studies evaluating the addition of uproleselan to standard-of-care regimens for patients with AML, why uproleselan could affect the treatment paradigm across AML subtypes, and the rationale for pursuing minimal residual disease negativity as a clinical end point in AML.

Dr Sanai discusses the prevalence and grading of malignant meningiomas; common symptoms associated with these tumors; treatment modalities for high-grade disease; and more.

Dr Danish discusses barriers to using radiotherapy for the treatment of patients with metastatic lung and bone cancers; the novel capabilities of SCINTIX biology-guided technology; and how John Theurer Cancer Center plans to use this technology and help advance its role in the field of radiation oncology.

Dr Carlo-Stella discusses the FDA approval of glofitamab in relapsed/refractory DLBCL, key efficacy and safety findings from the NP30179 trial, and the benefits of glofitamab’s mechanism of action.

Dr Trent discusses the current role and significance of using MRD in gastrointestinal stromal tumor, current guidelines around mutation testing, and research seeking to expand the targeted therapy armamentarium.

In this episode of ‘How This is Building Me,’ Drs Camidge and Abbott discuss the road from bench scientist to biotechnology analyst, rules and regulations in the industry, and more.

As new data emerge in breast cancer, stepping back from the updates and shedding light on the standard practices as they exist in the clinic are crucial approaches to management of the disease.

Dr Lunning sits down with Kamdar to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.

Drs Khan and Kwendakwema discuss the methods and design of two studies investigating adverse financial events in patients with cancer, the future implications of these findings, and the importance of continued investigation in this area.

Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.

Dr Lunning sits down with Jeremy Abramson, MD, to discuss treatment options for patients with LBCL following relapse on their initial therapies, the potential role of surveillance imaging in certain subsets of this population, and the challenging differences that arise when treating patients with cellular therapy in clinical trials vs in the real-world setting.

Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.

Dr King discusses the need for improved guidance when determining the appropriate management strategy for patients with residual nonretroperitoneal testicular cancer and findings from a study on the association between the presence of teratoma in the primary orchiectomy and the rate of teratoma in this disease.

Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.